financetom
Business
financetom
/
Business
/
AI start-up Lore Machine in funding talks, rolls out visual-storytelling platform
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AI start-up Lore Machine in funding talks, rolls out visual-storytelling platform
Mar 5, 2024 6:29 AM

(Reuters) - Lore Machine, an artificial intelligence start-up that allows writers to convert stories into images, audio and animation, said it was in talks to raise funds and started rolling out its visual-storytelling platform to the public on Tuesday.

The company plans to charge between $10 and $160 per month for its platform that allows users to customize locations, characters and scenes, with the highest-priced tier aimed at enterprises.

Lore Machine is also in talks with venture capital firms for a fundraise, following a pre-seed funding round in January 2023 that included Dao Jones, 100 Acre Ventures and NZVC and financial details of which were not disclosed.

"We are considering it (fundraising) ... having conversations with the VC community ... we are profitable and have significant revenues in Q4 and Q1 of this year from our partnerships," Lore Machine founder and CEO Thobey Campion told Reuters.

Campion did not provide details about the company's revenue and profit figures.

Lore Machine said it sees a large opportunity in the marketing industry and the company created an ad for HP's gaming computers that was aired in China.

The start-up is in talks for partnerships with 20 software platforms and content partners, and is working on a version of the platform that would allow enterprises to train the model with their in-house styles.

While using AI to generate visuals from text inputs is not new, Lore Machine is looking to stand out in the market by allowing longer prompts of up to 30,000 words.

The company creates visuals by using the popular Stable Diffusion AI image generator, but has built its own technology to synthesize text.

The platform will allow text inputs of up to 500,000 words in a couple of months, Campion added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Laramide Resources Reports Final Results from 2024 Drill Campaign at Westmoreland Project in Australia
Laramide Resources Reports Final Results from 2024 Drill Campaign at Westmoreland Project in Australia
Feb 21, 2025
08:16 AM EST, 02/21/2025 (MT Newswires) -- Laramide Resources ( LMRXF ) reported Friday final results from its 2024 drill campaign at the Westmoreland uranium project in Australia. Highlights include 8.00 meters at 325.61 parts per million (ppm) uranium from the Junnagunna deposit, 3.00 meters at 853.74 ppm uranium from the Amphitheatre deposit, and 260.04 ppm uranium and 1,082.19 ppm...
Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises
Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises
Feb 21, 2025
08:16 AM EST, 02/21/2025 (MT Newswires) -- Intra-Cellular Therapies ( ITCI ) reported a Q4 net loss Friday of $0.16 per diluted share, compared with a loss of $0.29 a year earlier. Analysts polled by FactSet expected a loss of $0.07. Total revenue for the quarter ended Dec. 31 was $199.2 million, up from $132.1 million a year earlier. Analysts...
Neurocrine Biosciences Approves $500 Million Share Repurchase Program
Neurocrine Biosciences Approves $500 Million Share Repurchase Program
Feb 21, 2025
08:18 AM EST, 02/21/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Friday its board authorized a new share repurchase program allowing the company to buy back up to $500 million of its shares. The company said the new authorization is in addition to the $300 million accelerated repurchase program launched in October 2024, which was completed in early...
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch
Feb 21, 2025
(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ending its tumultuous journey in the public markets as it struggled with a severe cash crunch. Bluebird bio, which raised going concern doubts for the first time three years ago, laid off about 25% of its workforce in 2024...
Copyright 2023-2026 - www.financetom.com All Rights Reserved